{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:16:48Z","timestamp":1781878608975,"version":"3.54.5"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","award":["EL2022"],"award-info":[{"award-number":["EL2022"]}],"id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Prix Ruban Rose","award":["2020"],"award-info":[{"award-number":["2020"]}]},{"name":"LYRINCAN","award":["INCA-DGOS-INSERM 12563"],"award-info":[{"award-number":["INCA-DGOS-INSERM 12563"]}]},{"name":"NetSarc","award":["INCA"],"award-info":[{"award-number":["INCA"]}]},{"name":"InterSARC","award":["INCA"],"award-info":[{"award-number":["INCA"]}]},{"DOI":"10.13039\/501100022238","name":"LabEx DEvweCAN","doi-asserted-by":"crossref","award":["ANR-10-LABX-0061"],"award-info":[{"award-number":["ANR-10-LABX-0061"]}],"id":[{"id":"10.13039\/501100022238","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100020147","name":"EURACAN","doi-asserted-by":"crossref","award":["EC 739521"],"award-info":[{"award-number":["EC 739521"]}],"id":[{"id":"10.13039\/501100020147","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Soft tissue sarcomas (STS) are heterogeneous and pro-metastatic tumors. Identification of accurate prognostic factors and novel therapeutic targets are crucial. CSPG4 is a cell surface proteoglycan with oncogenic functions. It recently emerged as a potential target for immunotherapy, including cell therapy based on CSPG4-specific chimeric antigen receptor (CAR)-redirected cytokine-induced killer lymphocytes (CSPG4-CAR.CIKs) in STS. However, expression of CSPG4 is poorly known in STS so far.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We analyzed CSPG4 gene expression in 1378 localized STS clinical samples, and searched for correlations with clinicopathological data, including disease-free survival (DFS), and with tumor immune features.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>CSPG4 expression was heterogeneous across samples. High expression was associated with younger patients\u2019 age, more frequent undifferentiated pleomorphic sarcoma and myxofibrosarcoma pathological subtypes, more frequent internal trunk tumor site, and more CINSARC high-risk samples. No correlation existed with pathological tumor size and grade, and tumor depth. Patients with high CSPG4 expression displayed 49% (95% CI 42\u201357) 5-year DFS <jats:italic>versus<\/jats:italic> 61% (95% CI 56\u201368) in patients with low expression (p\u2009=\u20093.17E\u221203), representing a 49% increased risk of event in the \u201c<jats:italic>CSPG4<\/jats:italic>-high\u201d group (HR\u2009=\u20091.49, 95% CI 1.14\u20131.94). This unfavorable prognostic value persisted in multivariate analysis, independently from other variables. There were significant differences in immune variables between \u201c<jats:italic>CSPG4<\/jats:italic>-high\u201d and \u201c<jats:italic>CSPG4<\/jats:italic>-low\u201d tumors. The \"<jats:italic>CSPG4<\/jats:italic>-low\" tumors displayed profiles suggesting higher anti-tumor cytotoxic immune response and higher potential vulnerability to immune checkpoint inhibitors (ICI). By contrast, the \"<jats:italic>CSPG4<\/jats:italic>-high\" tumors displayed profiles implying an immune-excluded tumor microenvironment, potentially induced by hypoxia, resulting from an immature chaotic microvasculature, and\/or the presence of contractile myofibroblasts.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Patients with \u201cCSPG4-high\u201d STS, theoretically candidate for CAR.CIKs, display shorter DFS and an immune environment unfavorable to vulnerability to CAR.CIKs, which could be improved by combining anti-angiogenic drugs able to normalize the tumor vasculature. By contrast, \u201cCSPG4-low\u201d STS are better candidates for immune therapy involving ICI.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-022-03679-y","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T07:03:03Z","timestamp":1665471783000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response"],"prefix":"10.1186","volume":"20","author":[{"given":"Laurys","family":"Boudin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"de Nonneville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Finetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9na","family":"Mescam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Le Cesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Birnbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Mamessier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0157-0959","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Bertucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,11]]},"reference":[{"key":"3679_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7\u201334.","journal-title":"CA Cancer J Clin"},{"key":"3679_CR2","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1002\/cncr.23332","volume":"112","author":"V Karavasilis","year":"2008","unstructured":"Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C, Judson I. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma. Cancer. 2008;112:1585\u201391.","journal-title":"Cancer"},{"key":"3679_CR3","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s12094-018-1848-x","volume":"20","author":"R Correa","year":"2018","unstructured":"Correa R, G\u00f3mez-Mill\u00e1n J, Lobato M, Fern\u00e1ndez A, Ordo\u00f1ez R, Castro C, Lupia\u00f1ez Y, Medina JA. Radiotherapy in soft-tissue sarcoma of the extremities. Clin Transl Oncol. 2018;20:1127\u201335.","journal-title":"Clin Transl Oncol"},{"key":"3679_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2217\/fon-2018-0076","volume":"14","author":"I Ray-Coquard","year":"2018","unstructured":"Ray-Coquard I, Serre D, Reichardt P, Mart\u00edn-Broto J, Bauer S. Options for treating different soft tissue sarcoma subtypes. Future Oncol Lond Engl. 2018;14:25\u201349.","journal-title":"Future Oncol Lond Engl"},{"key":"3679_CR5","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1002\/cncr.30191","volume":"122","author":"R Ratan","year":"2016","unstructured":"Ratan R, Patel SR. Chemotherapy for soft tissue sarcoma. Cancer. 2016;122:2952\u201360.","journal-title":"Cancer"},{"key":"3679_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3747\/co.27.5407","volume":"27","author":"O Ayodele","year":"2020","unstructured":"Ayodele O, Razak ARA. Immunotherapy in soft-tissue sarcoma. Curr Oncol. 2020;27:17\u201323.","journal-title":"Curr Oncol"},{"key":"3679_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1200\/JCO.2017.75.1610","volume":"36","author":"SM Pollack","year":"2018","unstructured":"Pollack SM, Ingham M, Spraker MB, Schwartz GK. Emerging targeted and immune-based therapies in sarcoma. J Clin Oncol. 2018;36:125\u201335.","journal-title":"J Clin Oncol"},{"key":"3679_CR8","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1200\/JCO.1997.15.1.350","volume":"15","author":"L Guillou","year":"1997","unstructured":"Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, Vilain MO, Mandard AM, Le Doussal V, Leroux A, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 1997;15:350\u201362.","journal-title":"J Clin Oncol"},{"key":"3679_CR9","doi-asserted-by":"publisher","first-page":"iv51","DOI":"10.1093\/annonc\/mdy096","volume":"29","author":"PG Casali","year":"2018","unstructured":"Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv51-67.","journal-title":"Ann Oncol."},{"key":"3679_CR10","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/nm.2174","volume":"16","author":"F Chibon","year":"2010","unstructured":"Chibon F, Lagarde P, Salas S, P\u00e9rot G, Brouste V, Tirode F, Lucchesi C, de Reynies A, Kauffmann A, Bui B, et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med. 2010;16:781\u20137.","journal-title":"Nat Med"},{"key":"3679_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003687","volume":"10","author":"F Bertucci","year":"2022","unstructured":"Bertucci F, Niziers V, de Nonneville A, Finetti P, Mescam L, Mir O, Italiano A, Le Cesne A, Blay JY, Ceccarelli M, et al. Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature. J Immunother Cancer. 2022;10: e003687.","journal-title":"J Immunother Cancer"},{"key":"3679_CR12","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.3389\/fimmu.2017.01911","volume":"8","author":"KM Ilieva","year":"2017","unstructured":"Ilieva KM, Cheung A, Mele S, Chiaruttini G, Crescioli S, Griffin M, Nakamura M, Spicer JF, Tsoka S, Lacy KE, et al. Chondroitin sulfate proteoglycan 4 and its potential as an antibody immunotherapy target across different tumor types. Front Immunol. 2017;8:1911.","journal-title":"Front Immunol"},{"key":"3679_CR13","doi-asserted-by":"publisher","first-page":"530","DOI":"10.7150\/thno.10824","volume":"5","author":"PA Nicolosi","year":"2015","unstructured":"Nicolosi PA, Dallatomasina A, Perris R. Theranostic impact of NG2\/CSPG4 proteoglycan in cancer. Theranostics. 2015;5:530\u201344.","journal-title":"Theranostics"},{"key":"3679_CR14","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1093\/jnci\/djq343","volume":"102","author":"X Wang","year":"2010","unstructured":"Wang X, Osada T, Wang Y, Yu L, Sakakura K, Katayama A, McCarthy JB, Brufsky A, Chivukula M, Khoury T, et al. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. J Natl Cancer Inst. 2010;102:1496\u2013512.","journal-title":"J Natl Cancer Inst"},{"key":"3679_CR15","doi-asserted-by":"publisher","first-page":"5352","DOI":"10.1158\/1078-0432.CCR-12-0628","volume":"18","author":"Z Rivera","year":"2012","unstructured":"Rivera Z, Ferrone S, Wang X, Jube S, Yang H, Pass HI, Kanodia S, Gaudino G, Carbone M. CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma. Clin Cancer Res. 2012;18:5352\u201363.","journal-title":"Clin Cancer Res"},{"key":"3679_CR16","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/14653240902923153","volume":"11","author":"I Kozanoglu","year":"2009","unstructured":"Kozanoglu I, Boga C, Ozdogu H, Sozer O, Maytalman E, Yazici AC, Sahin FI. Human bone marrow mesenchymal cells express NG2: possible increase in discriminative ability of flow cytometry during mesenchymal stromal cell identification. Cytotherapy. 2009;11:527\u201333.","journal-title":"Cytotherapy"},{"key":"3679_CR17","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1089\/ten.tea.2012.0649","volume":"19","author":"KC Russell","year":"2013","unstructured":"Russell KC, Tucker HA, Bunnell BA, Andreeff M, Schober W, Gaynor AS, Strickler KL, Lin S, Lacey MR, O\u2019Connor KC. Cell-surface expression of neuron-glial antigen 2 (NG2) and melanoma cell adhesion molecule (CD146) in heterogeneous cultures of marrow-derived mesenchymal stem cells. Tissue Eng Part A. 2013;19:2253\u201366.","journal-title":"Tissue Eng Part A"},{"key":"3679_CR18","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.celrep.2016.06.058","volume":"16","author":"S Sato","year":"2016","unstructured":"Sato S, Tang YJ, Wei Q, Hirata M, Weng A, Han I, Okawa A, Takeda S, Whetstone H, Nadesan P, et al. Mesenchymal tumors can derive from Ng2\/Cspg4-expressing pericytes with \u03b2-catenin modulating the neoplastic phenotype. Cell Rep. 2016;16:917\u201327.","journal-title":"Cell Rep"},{"key":"3679_CR19","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1158\/1078-0432.CCR-07-1712","volume":"14","author":"C-H Lee","year":"2008","unstructured":"Lee C-H, Espinosa I, Vrijaldenhoven S, Subramanian S, Montgomery KD, Zhu S, Marinelli RJ, Peterse JL, Poulin N, Nielsen TO, et al. Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin Cancer Res. 2008;14:1423\u201330.","journal-title":"Clin Cancer Res"},{"key":"3679_CR20","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3390\/cancers13030363","volume":"13","author":"A Koumarianou","year":"2021","unstructured":"Koumarianou A, Duran-Moreno J. The sarcoma immune landscape: emerging challenges, prognostic significance and prospective impact for immunotherapy approaches. Cancers. 2021;13:363.","journal-title":"Cancers"},{"key":"3679_CR21","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3390\/cancers13020360","volume":"13","author":"V Siozopoulou","year":"2021","unstructured":"Siozopoulou V, Domen A, Zwaenepoel K, Van Beeck A, Smits E, Pauwels P, Marcq E. Immune checkpoint inhibitory therapy in sarcomas: is there light at the end of the tunnel? Cancers. 2021;13:360.","journal-title":"Cancers"},{"key":"3679_CR22","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","volume":"19","author":"SP D\u2019Angelo","year":"2018","unstructured":"D\u2019Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, Antonescu CR, Horvath E, Tap WD, Schwartz GK, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018;19:416\u201326.","journal-title":"Lancet Oncol"},{"key":"3679_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01821-3","author":"A Italiano","year":"2022","unstructured":"Italiano A, Bessede A, Pulido M, Bompas E, Piperno-Neumann S, Chevreau C, Penel N, Bertucci F, Toulmonde M, Bellera C, et al. Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. Nat Med. 2022. https:\/\/doi.org\/10.1038\/s41591-022-01821-3.","journal-title":"Nat Med"},{"key":"3679_CR24","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41571-022-00619-z","volume":"19","author":"WH Fridman","year":"2022","unstructured":"Fridman WH, Meylan M, Petitprez F, Sun C-M, Italiano A, Saut\u00e8s-Fridman C. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat Rev Clin Oncol. 2022;19:441\u201357.","journal-title":"Nat Rev Clin Oncol"},{"key":"3679_CR25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/imr.12774","volume":"290","author":"E Jacoby","year":"2019","unstructured":"Jacoby E, Shahani SA, Shah NN. Updates on CAR T-cell therapy in B-cell malignancies. Immunol Rev. 2019;290:39\u201359.","journal-title":"Immunol Rev"},{"key":"3679_CR26","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509\u201318.","journal-title":"N Engl J Med"},{"key":"3679_CR27","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1182\/blood-2006-04-017061","volume":"108","author":"J Vera","year":"2006","unstructured":"Vera J, Savoldo B, Vigouroux S, Biagi E, Pule M, Rossig C, Wu J, Heslop HE, Rooney CM, Brenner MK, et al. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood. 2006;108:3890\u20137.","journal-title":"Blood"},{"key":"3679_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.795164","volume":"13","author":"P Safarzadeh Kozani","year":"2022","unstructured":"Safarzadeh Kozani P, Safarzadeh Kozani P, Ahmadi Najafabadi M, Yousefi F, Mirarefin SMJ, Rahbarizadeh F. Recent advances in solid tumor CAR-T cell therapy: driving tumor cells from hero to zero? Front Immunol. 2022;13: 795164.","journal-title":"Front Immunol"},{"key":"3679_CR29","doi-asserted-by":"publisher","first-page":"E2839","DOI":"10.3390\/ijms20112839","volume":"20","author":"R Rotolo","year":"2019","unstructured":"Rotolo R, Leuci V, Donini C, Cykowska A, Gammaitoni L, Medico G, Valabrega G, Aglietta M, Sangiolo D. CAR-based strategies beyond T lymphocytes: integrative opportunities for cancer adoptive immunotherapy. Int J Mol Sci. 2019;20:E2839.","journal-title":"Int J Mol Sci"},{"key":"3679_CR30","doi-asserted-by":"publisher","first-page":"6321","DOI":"10.1158\/1078-0432.CCR-20-0357","volume":"26","author":"V Leuci","year":"2020","unstructured":"Leuci V, Donini C, Grignani G, Rotolo R, Mesiano G, Fiorino E, Gammaitoni L, D\u2019Ambrosio L, Merlini A, Landoni E, et al. CSPG4-specific CAR.CIK lymphocytes as a novel therapy for the treatment of multiple soft-tissue sarcoma histotypes. Clin Cancer Res. 2020;26:6321\u201334.","journal-title":"Clin Cancer Res."},{"key":"3679_CR31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/jor.20694","volume":"27","author":"MS Benassi","year":"2009","unstructured":"Benassi MS, Pazzaglia L, Chiechi A, Alberghini M, Conti A, Cattaruzza S, Wassermann B, Picci P, Perris R. NG2 expression predicts the metastasis formation in soft-tissue sarcoma patients. J Orthop Res. 2009;27:135\u201340.","journal-title":"J Orthop Res"},{"key":"3679_CR32","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/jmcb\/mjt010","volume":"5","author":"S Cattaruzza","year":"2013","unstructured":"Cattaruzza S, Nicolosi PA, Braghetta P, Pazzaglia L, Benassi MS, Picci P, Lacrima K, Zanocco D, Rizzo E, Stallcup WB, et al. NG2\/CSPG4-collagen type VI interplays putatively involved in the microenvironmental control of tumour engraftment and local expansion. J Mol Cell Biol. 2013;5:176\u201393.","journal-title":"J Mol Cell Biol"},{"key":"3679_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ejca.2019.07.020","volume":"120","author":"C Truntzer","year":"2019","unstructured":"Truntzer C, Isambert N, Arnould L, Ladoire S, Ghiringhelli F. Prognostic value of transcriptomic determination of tumour-infiltrating lymphocytes in localised breast cancer. Eur J Cancer. 2019;120:97\u2013106.","journal-title":"Eur J Cancer Oxf Engl"},{"key":"3679_CR34","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","volume":"39","author":"G Bindea","year":"2013","unstructured":"Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39:782\u201395.","journal-title":"Immunity"},{"key":"3679_CR35","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.cell.2018.08.067","volume":"175","author":"J Kinchen","year":"2018","unstructured":"Kinchen J, Chen HH, Parikh K, Antanaviciute A, Jagielowicz M, Fawkner-Corbett D, Ashley N, Cubitt L, Mellado-Gomez E, Attar M, et al. Structural remodeling of the human colonic mesenchyme in inflammatory bowel disease. Cell. 2018;175:372-386.e17.","journal-title":"Cell"},{"key":"3679_CR36","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","volume":"9","author":"E Elyada","year":"2019","unstructured":"Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhart RA, Teinor JA, Belleau P, Biffi G, Lucito MS, et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 2019;9:1102\u201323.","journal-title":"Cancer Discov"},{"key":"3679_CR37","doi-asserted-by":"publisher","first-page":"6994","DOI":"10.1073\/pnas.0912708107","volume":"107","author":"ML Gatza","year":"2010","unstructured":"Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, Datto MB, Kelley M, Mathey-Prevot B, Potti A, et al. A pathway-based classification of human breast cancer. Proc Natl Acad Sci USA. 2010;107:6994\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3679_CR38","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1253654","volume":"6","author":"W Hendrickx","year":"2017","unstructured":"Hendrickx W, Simeone I, Anjum S, Mokrab Y, Bertucci F, Finetti P, Curigliano G, Seliger B, Cerulo L, Tomei S, et al. Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. OncoImmunology. 2017;6: e1253654.","journal-title":"OncoImmunology"},{"key":"3679_CR39","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127:2930\u201340.","journal-title":"J Clin Invest"},{"key":"3679_CR40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ajpath.2011.03.007","volume":"179","author":"D Coppola","year":"2011","unstructured":"Coppola D, Nebozhyn M, Khalil F, Dai H, Yeatman T, Loboda A, Mul\u00e9 JJ. Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am J Pathol. 2011;179:37\u201345.","journal-title":"Am J Pathol"},{"key":"3679_CR41","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160:48\u201361.","journal-title":"Cell"},{"key":"3679_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000974","volume":"8","author":"JC Thompson","year":"2020","unstructured":"Thompson JC, Davis C, Deshpande C, Hwang W-T, Jeffries S, Huang A, Mitchell TC, Langer CJ, Albelda SM. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma. J Immunother Cancer. 2020;8: e000974.","journal-title":"J Immunother Cancer"},{"key":"3679_CR43","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.cell.2017.10.014","volume":"171","author":"A Abeshouse","year":"2017","unstructured":"Abeshouse A, Adebamowo C, Adebamowo SN, Akbani R, Akeredolu T, Ally A, Anderson ML, Anur P, Appelbaum EL, Armenia J, et al. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell. 2017;171:950-965.e28.","journal-title":"Cell"},{"key":"3679_CR44","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1074\/jbc.M117.805051","volume":"293","author":"S-HC Hsu","year":"2018","unstructured":"Hsu S-HC, Nadesan P, Puviindran V, Stallcup WB, Kirsch DG, Alman BA. Effects of chondroitin sulfate proteoglycan 4 (NG2\/CSPG4) on soft-tissue sarcoma growth depend on tumor developmental stage. J Biol Chem. 2018;293:2466\u201375.","journal-title":"J Biol Chem."},{"key":"3679_CR45","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.3390\/cancers14051306","volume":"14","author":"A de Nonneville","year":"2022","unstructured":"de Nonneville A, Finetti P, Picard M, Monneur A, Pantaleo MA, Astolfi A, Ostrowski J, Birnbaum D, Mamessier E, Bertucci F. CSPG4 expression in GIST is associated with better prognosis and strong cytotoxic immune response. Cancers. 2022;14:1306.","journal-title":"Cancers"},{"key":"3679_CR46","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/j.1755-148X.2011.00929.x","volume":"24","author":"MA Price","year":"2011","unstructured":"Price MA, Colvin Wanshura LE, Yang J, Carlson J, Xiang B, Li G, Ferrone S, Dudek AZ, Turley EA, McCarthy JB. CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma. Pigment Cell Melanoma Res. 2011;24:1148\u201357.","journal-title":"Pigment Cell Melanoma Res"},{"key":"3679_CR47","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00401-011-0867-2","volume":"122","author":"A Svendsen","year":"2011","unstructured":"Svendsen A, Verhoeff JJC, Immervoll H, Br\u00f8gger JC, Kmiecik J, Poli A, Netland IA, Prestegarden L, Planagum\u00e0 J, Torsvik A, et al. Expression of the progenitor marker NG2\/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma. Acta Neuropathol (Berl). 2011;122:495\u2013510.","journal-title":"Acta Neuropathol (Berl)"},{"key":"3679_CR48","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.bbrc.2013.10.093","volume":"441","author":"NC Hsu","year":"2013","unstructured":"Hsu NC, Nien P-Y, Yokoyama KK, Chu P-Y, Hou M-F. High chondroitin sulfate proteoglycan 4 expression correlates with poor outcome in patients with breast cancer. Biochem Biophys Res Commun. 2013;441:514\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"3679_CR49","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1002\/ijc.28906","volume":"135","author":"R Warta","year":"2014","unstructured":"Warta R, Herold-Mende C, Chaisaingmongkol J, Popanda O, Mock A, Mogler C, Osswald F, Herpel E, K\u00fcstner S, Eckstein V, et al. Reduced promoter methylation and increased expression of CSPG4 negatively influences survival of HNSCC patients. Int J Cancer. 2014;135:2727\u201334.","journal-title":"Int J Cancer"},{"key":"3679_CR50","doi-asserted-by":"publisher","first-page":"6649","DOI":"10.3748\/wjg.v21.i21.6649","volume":"21","author":"L-L Lu","year":"2015","unstructured":"Lu L-L, Sun J, Lai J-J, Jiang Y, Bai L-H, Zhang L-D. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis. World J Gastroenterol. 2015;21:6649\u201359.","journal-title":"World J Gastroenterol"},{"key":"3679_CR51","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/ijc.2910280307","volume":"28","author":"BS Wilson","year":"1981","unstructured":"Wilson BS, Imai K, Natali PG, Ferrone S. Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies. Int J Cancer. 1981;28:293\u2013300.","journal-title":"Int J Cancer"},{"key":"3679_CR52","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3727\/096504014X14174484758503","volume":"22","author":"M Fenton","year":"2015","unstructured":"Fenton M, Whiteside TL, Ferrone S, Boyiadzis M. Chondroitin sulfate proteoglycan-4 (CSPG4)-specific monoclonal antibody 225.28 in detection of acute myeloid leukemia blasts. Oncol Res. 2015;22:117\u201321.","journal-title":"Oncol Res."},{"key":"3679_CR53","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.spinee.2015.11.059","volume":"16","author":"AJ Schoenfeld","year":"2016","unstructured":"Schoenfeld AJ, Wang X, Wang Y, Hornicek FJ, Nielsen GP, Duan Z, Ferrone S, Schwab JH. CSPG4 as a prognostic biomarker in chordoma. Spine J. 2016;16:722\u20137.","journal-title":"Spine J"},{"key":"3679_CR54","doi-asserted-by":"publisher","first-page":"eaao2731","DOI":"10.1126\/scitranslmed.aao2731","volume":"10","author":"S Pellegatta","year":"2018","unstructured":"Pellegatta S, Savoldo B, Di Ianni N, Corbetta C, Chen Y, Patan\u00e9 M, Sun C, Pollo B, Ferrone S, DiMeco F, et al. Constitutive and TNF\u03b1-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy. Sci Transl Med. 2018;10:eaao2731.","journal-title":"Sci Transl Med."},{"key":"3679_CR55","doi-asserted-by":"publisher","first-page":"175883591985549","DOI":"10.1177\/1758835919855491","volume":"11","author":"F Riccardo","year":"2019","unstructured":"Riccardo F, Tarone L, Iussich S, Giacobino D, Arigoni M, Sammartano F, Morello E, Martano M, Gattino F, Maria RD, et al. Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma. Ther Adv Med Oncol. 2019;11:1758835919855491.","journal-title":"Ther Adv Med Oncol"},{"key":"3679_CR56","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1073\/pnas.89.2.466","volume":"89","author":"A Mittelman","year":"1992","unstructured":"Mittelman A, Chen ZJ, Yang H, Wong GY, Ferrone S. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA. 1992;89:466\u201370.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3679_CR57","first-page":"415","volume":"54","author":"A Mittelman","year":"1994","unstructured":"Mittelman A, Chen ZJ, Liu CC, Hirai S, Ferrone S. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Cancer Res. 1994;54:415\u201321.","journal-title":"Cancer Res"},{"key":"3679_CR58","first-page":"705","volume":"1","author":"A Mittelman","year":"1995","unstructured":"Mittelman A, Chen GZ, Wong GY, Liu C, Hirai S, Ferrone S. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma. Clin Cancer Res. 1995;1:705\u201313.","journal-title":"Clin Cancer Res"},{"key":"3679_CR59","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3892\/ijo.2021.5250","volume":"59","author":"K Uranowska","year":"2021","unstructured":"Uranowska K, Samadaei M, Kalic T, Pinter M, Breiteneder H, Hafner C. A chondroitin sulfate proteoglycan 4-specific monoclonal antibody inhibits melanoma cell invasion in a spheroid model. Int J Oncol. 2021;59:70.","journal-title":"Int J Oncol"},{"key":"3679_CR60","doi-asserted-by":"publisher","first-page":"E1029","DOI":"10.3390\/cancers12041029","volume":"12","author":"RM Hoffmann","year":"2020","unstructured":"Hoffmann RM, Crescioli S, Mele S, Sachouli E, Cheung A, Chui CK, Andriollo P, Jackson PJM, Lacy KE, Spicer JF, et al. A Novel Antibody-Drug Conjugate (ADC) delivering a DNA mono-alkylating payload to Chondroitin Sulfate Proteoglycan (CSPG4)-expressing melanoma. Cancers. 2020;12:E1029.","journal-title":"Cancers"},{"key":"3679_CR61","doi-asserted-by":"publisher","first-page":"E5942","DOI":"10.3390\/ijms20235942","volume":"20","author":"DC Harrer","year":"2019","unstructured":"Harrer DC, D\u00f6rrie J, Schaft N. CSPG4 as target for CAR-T-cell therapy of various tumor entities-merits and challenges. Int J Mol Sci. 2019;20:E5942.","journal-title":"Int J Mol Sci"},{"key":"3679_CR62","first-page":"3516","volume":"5","author":"J Tomlinson","year":"1999","unstructured":"Tomlinson J, Barsky SH, Nelson S, Singer S, Pezeshki B, Lee MC, Eilber F, Nguyen M. Different patterns of angiogenesis in sarcomas and carcinomas. Clin Cancer Res. 1999;5:3516\u201322.","journal-title":"Clin Cancer Res"},{"key":"3679_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100178","volume":"9","author":"S Keleg","year":"2014","unstructured":"Keleg S, Titov A, Heller A, Giese T, Tjaden C, Ahmad SS, Gaida MM, Bauer AS, Werner J, Giese NA. Chondroitin sulfate proteoglycan CSPG4 as a novel hypoxia-sensitive marker in pancreatic tumors. PLoS ONE. 2014;9: e100178.","journal-title":"PLoS ONE"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03679-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-022-03679-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03679-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T08:41:45Z","timestamp":1665477705000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-022-03679-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,11]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3679"],"URL":"https:\/\/doi.org\/10.1186\/s12967-022-03679-y","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,11]]},"assertion":[{"value":"6 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our <i>in silico<\/i> study is based upon public data from published studies in which the informed patient's consent to participate and the ethics and institutional review board were already obtained by authors. The study was approved by our institutional review board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ALC received consulting fees from Pharmamar, Bayer, and Deciphera. The other authors have declared no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"464"}}